

KIDS Policy Delphi
Round 2 Data Analysis (See Appendix A)

I. Re-ratings

POLICY DELPHI ITEM	DIMENSION	RATING ⁱ				CONSENSUS	SUPPORT	POLARITY
		1	2	3	4			
Parental authorization for ongoing, or future unspecified research should include the provision of information related to existing data governance.	Relative Importance	7	4	1	0	High	SS-ws	None (0.42)
	Desirability	8	4	0	0	High	SS-ws	None (0.22)
Values conveyed by family, legal guardians or primary care givers should be respected when possible.	Relative Importance	5	7	0	0	High	ws	None (0.24)
	Feasibility	1	4	7	0	High	wo	None (0.42)
All professionals involved in processes of data sharing and data-intensive research have the responsibility to balance potential benefits and risks and discuss these with parents at the time of consent.	Desirability	7	4	1	0	High	SS-ws	None (0.42)
	Feasibility	3	6	2	1	Med	ws	None (0.74)
Anonymized pediatric data should be made available via publicly accessible databases.	Desirability	5	2	3	2	Low	ws-wo	Strong (1.31)
	Feasibility	5	3	4	0	Med	ws-wo	None (0.74)
Identifiable pediatric genomic and associated clinical data should be coded and made available through a controlled or registered access process.	Desirability	8	1	1	2	Med	SS	Strong (1.35)
	Feasibility	4	5	2	1	Med	SS-ws	None (0.83)
Providing children and their parents the opportunity to share genomic and associated clinical data is an obligation of those who generate such data.	Desirability	8	1	2	1	Med	SS	Weak (1.06)
	Feasibility	3	2	5	2	Low	wo	Weak (1.08)

ⁱ **Rating of 1** = Very important, Very desirable, Definitely feasible; **Rating of 2** = Somewhat important, somewhat desirable, possibly feasible; **Rating of 3** = Unimportant, Somewhat undesirable, Possibly not feasible; **Rating of 4** = Unimportant, Very undesirable, Definitely not feasible

Incidental (secondary) findings of clinically actionable, validated genomic results should be made available.	Desirability	6	4	2	0	High	SS-ws	None (0.41)
	Feasibility	0	9	2	1	High	ws	None (0.64)

II. Amendments

AMENDED STATEMENT	AGREE	DISAGREE	DECISION
Professionals involved in consent processes related to data sharing and data-intensive research have the responsibility to balance potential benefits and risks. A trained designate should be available to discuss these with parents at the time of consent.	9 (75%)	3 (25%)	Adopt amendment
Anonymized pediatric data should be made available via publicly accessible databases.	6 (50%)	6 (50%)	Undecided
Identifiable pediatric genomic and associated data should be coded and made available through a controlled access process.	6 (50%)	6 (50%)	Undecided
Providing children and their families the opportunity to share their genomic and associated data is an obligation of researchers.	5 (42%)	7 (58%)	Reject amendment
Incidental (secondary) findings of clinically actionable, validated genomic results should be made available.	8 (67%)	4 (33%)	Adopt new statement

IN YOUR VIEW, WHAT (IF ANYTHING) COULD BE DONE TO ENHANCE THE FEASIBILITY OF THE FOLLOWING STATEMENTS?

Statement	Main themes after thematic coding
Values conveyed by family, legal guardians or primary care givers should be respected when possible	<ul style="list-style-type: none"> No barriers to feasibility beyond those associated with the consent process [1]
	<ul style="list-style-type: none"> Improve ability to assess values [2] via <ul style="list-style-type: none"> → standardization of questionnaires [1] → tools [1]
	<ul style="list-style-type: none"> Differentiate the need to assess values between research and clinical contexts [1]
	<ul style="list-style-type: none"> Include family/caregivers at the time of consent [1]
	<ul style="list-style-type: none"> Allow data sharing choices that <ul style="list-style-type: none"> → are not conditional on research participation [1] → restrict future unspecific uses of data [1] → mandates re-consent for each use [1]
	<ul style="list-style-type: none"> Improve bidirectional communication [1]
All professionals involved in processes of data sharing and data-intensive research have the responsibility to balance potential benefits and risks and discuss these with parents at the time of consent	<ul style="list-style-type: none"> Basic requirement as per ethics principles <ul style="list-style-type: none"> → informed consent [2] → responsible conduct of research [1]
	<ul style="list-style-type: none"> Ensure standards for consent process via <ul style="list-style-type: none"> → verifying the process is commensurate with levels of risk the data sharing poses [1] → improving readability of consent wording
	<ul style="list-style-type: none"> Barriers to feasibility are technical aspects of data security and quality which prevent realistic understandings of risks and benefits within the research enterprise
	<ul style="list-style-type: none"> Feasibility of balancing unrealistic after consent due to other clinician demands Limit the obligation to some, but not all health professionals because <ul style="list-style-type: none"> → of an inability to discuss potential benefits risks or consent families [1] → infrequent or indirect contact with families [3] → the obligation is too extensive [1]
	<ul style="list-style-type: none"> Enhance researcher education/knowledge on data sharing benefits and risks [2]
Providing children and their parents the opportunity to share genomic and associated	<ul style="list-style-type: none"> Improve data infrastructures and adequate funding resources to support them [3] <ul style="list-style-type: none"> → specifically multicentre databases [1]
	<ul style="list-style-type: none"> Feasibility strengthened by a rights-based or ethics principle that supports the statement [1]

clinical data is an obligation of those who generate such data	<ul style="list-style-type: none"> • Establish a common information sharing platform
	<ul style="list-style-type: none"> • Specify types of sharing that can be expected e.g. return of material findings
	<ul style="list-style-type: none"> • There is no such obligation
	<ul style="list-style-type: none"> • Additional human and material resources needed

Appendix A—Non-parametric thresholds for consensus, polarity and support used in Rounds 1 and 2*

CONSENSUS—A measure of the degree to which the group was able to agree on *support* (strong, weak etc).

High	70% of ratings in 1 category, or 80% in 2 contiguous categories
Med	60% of ratings in 1 category, or 70% in 2 contiguous categories
Low	50% of ratings in 1 category, or 60% in 2 contiguous categories

SUPPORT—Support indicates where the group’s support lay when there was *consensus*. Categories include:

SS—Strong support

SS-~~ws~~—Strong, to weak support

~~ws~~—Weak support

WS-~~wo~~: Weak support to weak opposition

WO—Weak opposition

~~wo~~-SO: Weak, to strong opposition

SO—Strong opposition

When consensus is ‘none’, support is always ‘ambiguous’. It can also be ‘ambiguous’ when:

(1) the level of consensus is ‘low’ and the ratings are divided equally between two categories (e.g. rating distributions of 10 0 0 10, or 10 0 10 0);

(2) the ratings are distributed in a pattern such as: 4 10 4 2. In this case, consensus would be considered ‘medium’- but the point of support could be either of ‘SS-WS’ or ‘WS-WO’.

POLARITY*—Measures whether the group’s ratings were polarized (e.g. 10 0 0 10 is a strongly polarized distribution). Categories include strong, weak, none. Polarity is determined using the variance of the distribution.

	De Loe 1995	Rahimzadeh 2018
Strong	Higher than 1.5	Higher than 1.1
Weak	Between 1.2 and 1.5	Between 0.8976 and 1.1
None	Less than 1.2	Less than 0.8976

*modified from de Loe 1995; transformed 80th percentile categories based on highest variance of the distribution calculated in the Round 1 dataset (1.122)